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A B S T R A C T
Hemophilia A is an ideal target for cell or gene therapy because a mild increase in coagulation factor VIII (FVIII) improves symptoms in patients with severe
hemophilia A. In this study, we used CRISPR/Cas9 to insert FVIII cDNA into exon 1 of the mutant FVIII locus in induced pluripotent stem cells (iPSCs) from a
hemophilia A patient. This gene-modified YCMi001-B-1 line maintained its pluripotency, formed all three germ layers, and had a normal karyotype. In addition, FVIII
expression was confirmed in YCMi001-B-1-derived endothelial cells.
1. Resources table










Type of cell line iPSC
Origin Human
Additional origin info Age: 44
Sex: Male
Ethnicity if known: Asian (Korean)






Type of Modification Transgene knock-in
Associated disease Hemophilia A
Gene/locus FVIII/Xq28.1
Method of modification CRISPR/Cas9






Date archived/stock date 2017/3
Cell line repository/bank https://hpscreg.eu/cell-line/YCMi001-B-1
Ethical approval Ethical committee: Yonsei university health system,
Severance Hospital, Institutional review board approval
number: #4-2012-0028
2. Resource utility
The YCMi001-B-1 line was generated by target-specific knock-in of
the B-domain deleted form of FVIII cDNA into the FVIII locus of iPSCs
from a hemophilia A patient. The YCMi001-B-1 line can be used for
autologous cell therapy in Hemophilia A patients.
3. Resource details
Hemophilia A is caused by mutations in FVIII that inhibit coagula-
tion (Mannucci and Tuddenham, 2001). Previously, we generated an
induced pluripotent stem cell (iPSC) line, Del-iPSC-Epi6, using adipose
tissue-derived mesenchymal stem cells obtained from a hemophilia A
patient with a gross deletion of exons 8–22 in FVIII locus (Park et al.,
2019). In this study, we inserted the B-domain deleted form of FVIII
(BDD-FVIII) cDNA into exon 1 of FVIII locus in the Del-iPSC-Epi6 line
using CRISRP/Cas9 to restore FVIII expression. BDD-FVIII cDNA does
not contain a part of Exon 14 (~ 2.7 kb), and thus has a relatively small
size (~ 4.3 kb) which makes it easier for gene delivery and an enhanced
expression capability compared to the full-length FVIII cDNA (~ 7 kb),
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Fig. 1. Characterization of YCMi001-B-1 iPSC line.
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without affecting coagulation activity of FVIII (Mannucci and
Tuddenham, 2001). Thus, BDD-FVIII is widely used in gene therapy for
hemophilia A.
A schematic representation of the guide RNA target site and the
knock-in strategy to integrate the donor plasmid into the FVIII locus is
shown (Fig. 1A). In a previous study, we evaluated the cutting effi-
ciency of Cas9 using a single guide RNA (sgRNA) designed to cleave
exon 1 of the FVIII locus (Fig. 1A) (Sung et al., 2019). pcDNA4/BDD-
FVIII (Addgene #40135) was used to construct the FVIII cDNA donor
plasmid. The human cytomegalovirus immediate early enhancer and
the promoter of pcDNA4/BDD-FVIII were substituted with the 5′ left
homology arm (L arm) and a neomycin resistance cassette (NeoR)
flanked by two loxP sequences ligated to the 3′ end of the bovine
growth hormone (bGH) polyadenylation signal. The 3′ right homology
arm (R arm) was attached to the 3′ end of NeoR (Fig. 1A).
After electroporation with Cas9, sgRNA, and the FVIII cDNA donor
plasmids and following G418 selection, NeoR in the gene-corrected
iPSC lines was removed by Cre recombinase expression. To determine if
the correct gene was targeted, cells were screened by PCR amplification
for the Cas9 target site (F1/R1) and the 5′ (F1/R2) and 3′ (F2/R1)
knock-in junctions (Fig. 1B). PCR analysis using a F1/R1 primer set
confirmed that the YCMi001-B-1 clone demonstrated hemizygous in-
sertion of the donor vector at FVIII locus (Fig. 1B, upper panel) and
following sanger sequencing of the PCR amplicons revealed that the
donor plasmid incorporated correctly into exon 1 of the FVIII locus
(Fig. 1C).
Investigation of cells in bright field showed that the gene-modified
YCMi001-B-1 line maintained typical iPSC morphology (Fig. 1D). Real-
time PCR analysis showed that expression of pluripotent markers
(OCT4, SOX2, LIN28) was similar in YCMi001-B-1 cells and in parental
iPSCs from the patient (Fig. 1E). Immunocytochemistry of YCMi001-B-1
cells and colonies also confirmed uniform expression of pluripotent
markers (OCT4, SOX2, SSEA4, TRA-1-60) (Fig. 1F). The in vitro 3-germ
layer assay (ectoderm; NESTIN, mesoderm; α-SMA, endoderm; SOX17)
showed that the YCMi001-B-1 line differentiated normally (Fig. 1G).
Additionally, YCMi001-B-1 exhibited a normal 46, XY karyotype with
no detectable abnormalities and no trace of mycoplasma contamination
(Fig. 1H, I). Short tandem repeat (STR) analysis also showed that the
YCMi001-B-1 iPSCs and parental iPSCs were genetically identical
(Table 1).
Endothelial differentiation ability and knocked-in FVIII expression
was evaluated in the YCMi001-B-1 line as previously described
(Harding et al., 2017; Sung et al., 2019). Immunocytochemistry showed
that the YCMi001-B-1 line could differentiate into CD31- and vWF-
positive endothelial cells similar to the normal iPSC and the parental
iPSC line (Fig. 1J). Furthermore, PCR amplicons corresponding to exons
7–10 of the FVIII transcript (621 bp) were detected in endothelial cells
from the normal iPSCs and YCMi001-B-1, but were not detected in the
derivative from the patient iPSCs (Fig. 1K, upper panel). However, the
PCR products targeted to GAPDH (87 bp) as a control were detected in
derivatives from all three cell lines (Fig. 1K, bottom panel). Sanger
sequencing also revealed that FVIII transcripts in YCMi001-B-1 derived
endothelial cells had normal exon 7–10 sequences of FVIII cDNA
(Fig. 1L). These results indicated that YCMi001-B-1 restored FVIII
mRNA expression via gene correction.
4. Materials and methods
4.1. Cell cultures
iPSCs derived from a male healthy (normal) donor and a male
Hemophilia A patient with a gross deletion (Park et al., 2019) and the
YCMi001-B-1 line were cultured in STEMMACSTM iPSC-brew FX (STE-
MMACS medium; Miltenyi Biotec) in Matrigel (Corning)-coated dishes.
4.2. Generation of gene-corrected patient-derived iPSCs
Cas9 and sgRNA were purchased from ToolGen, Inc., Korea. For
electroporation, Y-27632-pretreated patient-derived iPSCs were dis-
sociated into single cells using TrypLE™ Select. Two micrograms of
Cas9, 2 μg sgRNA expression vector, and 4 μg donor plasmid were in-
troduced into 5 × 105 iPSC cells using a NeonR electroporator
(Invitrogen). The cells were reseeded in a Matrigel-coated dish and
cultured in STEMMACS medium supplemented with G418 for 2 d.
Then, 2 μg pCAG-Cre:GFP (Addgene #13776) was electroporated into
5 × 105 surviving iPSCs to remove NeoR. Genomic DNAs from iPSCs
were purified using the DNeasy Blood & Tissue Kit (QIAGEN) and PCR
amplification was performed using EmeraldAmp® GT PCR Master Mix
(TAKARA BIO Inc.) and primers listed in Table 2.
4.3. RNA extraction, cDNA synthesis, and real-time RT-PCR
Total RNA from cells was extracted using the Easy-Spin® Total RNA
Extraction kit (iNtRON Biotechnology) according to the manufacturer’s
instructions. Total RNA was converted to cDNA using PrimeScriptTM RT
Master Mix (TAKARA BIO Inc.). Transcript levels were evaluated via
real-time RT-PCR (RT-qPCR) using SYBR® Premix ExTaqTM (TAKARA
BIO Inc.) and the CFX96 Real-Time System (Bio-Rad). GAPDH was used
as the internal control. PrimeSTAR® Max DNA polymerase (TAKARA
BIO Inc.) was used to amplify the target site for semi-quantitative RT-
PCR. Primer sequences are listed in Table 2.
Table 1
Characterization and validation.
Classification Test Result Data
Morphology Photography Visual record of the line: Normal Fig. 1 panel D
Phenotype Qualitative analysis Immunocytochemistry Positive for pluripotency markers including OCT4, SOX2, SSEA4, and TRA-
1–60
Fig. 1 panel F
Quantitative analysis RT-qPCR Positive for pluripotency markers including OCT4, SOX2, LIN28 Fig. 1 panel E
Genotype Karyotype (G-banding) and resolution 46, XY
Resolution 550
Fig. 1 panel H
Identity Microsatellite PCR (mPCR) OR N/A
STR analysis 18 sites were tested and all matched Available with the authors
Mutation analysis Sequencing Hemizygous Fig. 1 panel B
Southern Blot OR WGS N/A
Microbiology and virology Mycoplasma Mycoplasma testing via PCR. Negative Fig. 1 panel I
Differentiation potential Spontaneous differentiation NESTIN (ectoderm); SOX17 (endoderm);
α-SMA (mesoderm)
Fig. 1 panel G
Donor screening HIV 1 + 2 Hepatitis B, Hepatitis C N/A
Genotype additional info Blood group genotyping N/A
HLA tissue typing N/A
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4.4. Immunocytochemistry
Cells were fixed with a 4% paraformaldehyde for 10 min, permea-
bilized with PBS containing 0.1% Triton X-100 for 10 min at room
temperature (RT) and then blocked with PBS containing 2% BSA for 1 h
at RT. After blocking, cells were incubated with primary antibody
overnight at 4 °C, washed, and incubated with secondary antibody for
30 min at RT (Table 2). Cells were mounted onto slides using mounting
medium containing 4′, 6-diamidino-2-phenylindole (Vector Labora-
tories). All images were captured with a fluorescence microscope
(Nikon Instruments Inc).
4.5. Differentiation into three germ layer cell types and endothelial cells
For the in vitro 3-germ layer assay, iPSC colonies were lifted and
embryonic bodies (EBs) were generated. EBs were maintained on low-
attachment plates in 5% FBS containing EB culture medium [DMEM/
F12 medium containing bFGF (PeproTech), 20% knockout serum re-
placement (Invitrogen), 1% nonessential amino acids (Invitrogen), and
0.1 mM 2-mercaptoethanol (Sigma-Aldrich)]. After 7 d, EBs were plated
onto matrigel-coated dishes and maintained for an additional 10 d to
allow for spontaneous differentiation. iPSCs were also differentiated
into endothelial cells as described previously (Harding et al., 2017;
Sung et al., 2019).
4.6. Karyotyping, mycoplasma testing and STR analysis
Standard G banding of metaphase spreads was performed at GenDix,
Inc., Korea. Cells were checked for the absence of mycoplasma
contamination at Cosmogenetech, Korea. YCMi001-B-1 and parental
iPSCs were sent to the Cosmogenetech (Korea) for STR analysis.
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Table 2
Reagents details.
Antibodies used for immunocytochemistry/flow-cytometry
Antibody Dilution Company cat # and RRID
Pluripotency markers Rabbit anti-OCT4 1:200 Santa Cruz, cat #sc-9081, RRID:AB_2167703
Rabbit anti-SOX2 1:200 Millipore, cat # AB5603 RRID:AB_304980
Mouse anti-TRA-1-60 1:100 Millipore, cat #MAB4360 RRID:AB_2277963
Mouse anti-SSEA4 1:200 Millipore, cat #MAB4304 RRID:AB_177629
Differentiation markers Rabbit anti-NESTIN 1:1000 Millipore, cat #ABD69 RRID:AB_2744681
Mouse anti-α-SMA 1:400 Sigma-Aldrich, cat #A5228 RRID:AB_262054
Goat anti-SOX17 1:200 Santa Cruz, cat#sc-17356 RRID:AB_2195655
Mouse anti-CD31 1:200 BD Pharmingen, cat#555444 RRID:AB_395837
Rabbit anti-vWF 1:500 Millipore, cat#AB7356 RRID:AB_92216
Secondary antibodies Donkey anti-rabbit IgG (H + L) highly cross-adsorbed secondary
antibody, Alexa Fluor 488
1:1000 Invitrogen, cat #A-21206 RRID:AB_2535792
Donkey anti-mouse IgG (H + L) highly cross-adsorbed secondary
antibody, Alexa Fluor 488
1:1000 Invitrogen, cat #A-21202 RRID:AB_141607
Donkey anti-mouse IgG (H + L) highly cross-adsorbed secondary
antibody, Alexa Fluor 594
1:1000 Invitrogen, cat #A-21203 RRID:AB_141633
Donkey anti-rabbit IgG (H + L) highly cross-adsorbed secondary
antibody, Alexa Fluor 594
1:1000 Invitrogen, cat #A-21207 RRID:AB_141637
Donkey anti-goat IgG (H + L) cross-adsorbed secondary antibody, Alexa
Fluor 594
1:1000 Invitrogen, cat #A-11058 RRID:AB_2534105
Primers
Target Forward/Reverse primer (5′-3′)
Genotyping Knock-in site (F1/R1: 2667 bp or 7409 bp) CTGTCATCTCTGCATCCTTGTACC/GGGAGCCAAACAGAAAGAACC
5′ Knock-in junction (F1/R2 : 1679 bp) CTGTCATCTCTGCATCCTTGTACC/GGCCTTGGCTTAGCGATGT
3′ Knock-in junction (F2/R1 : 1324 bp) ACAGGACCTCTACTGAGCGG/GGGAGCCAAACAGAAAGAACC
Pluripotency markers (qPCR) OCT4 (164 bp) CCTCACTTCACTGCACTGTA/CAGGTTTTCTTTCCCTAGCT
SOX2 (80 bp) TTCACATGTCCCAGCACTACCAGA/TCACATGTGTGAGAGGGGCAGTGT
LIN28 (129 bp) AGCCATATGGTAGCCTCATGTCCG/TCAATTCTGTGCCTCCGGGAGCAG
FVIII (qPCR) FVIII Exon 7 to Exon 10 (621 bp) TCTTGTGAGGAACCATCGCC/ACATCAGTGATTCCGTGAGGG
House-keeping gene (qPCR) GAPDH (87 bp) TGCACCACCAACTGCTTAGC/GGCATGGACTGTGGTCATGAG
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